oncology

Featured image of the article Unlocking new cancer targets: Oxford BioTherapeutics and Roche leverage OGAP®-Verify in strategic collaboration.

Unlocking new cancer targets: Oxford BioTherapeutics and Roche leverage OGAP®-Verify in strategic collaboration

Posted on by

SOPHIA ANTIPOLIS, France – April 11th, 2025 │ On March 19th, 2025, a collaboration was announced between Oxford BioTherapeutics (OBT) and Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. Targets will be identified via the OGAP®-Verify discovery platform of OBT, a proprietary database on membrane protein abundance, with around 7,000[…]

Featured image of the article Bristol Myers Squibb Acquired its Abecma Partner, 2seventy Bio.

Bristol Myers Squibb Acquired its Abecma Partner, 2seventy Bio

Posted on by

SOPHIA ANTIPOLIS, France – April 3rd, 2025 │ March 11th, Bristol Myers Squibb (BMS) announced a definitive merger agreement to acquire all of the outstanding shares of 2seventy bio for a total equity value of approximately $286 million. The company 2seventy bio decided to focus exclusively on Abecma which was the first B cell maturation[…]

Summary of Regeneron patented technologies.

Regeneron Strengthens Odronextamab Patent Portfolio While Adjusting Approval Strategy

Posted on by

SOPHIA ANTIPOLIS, France – March 7, 2025 │ A few days ago, Regeneron decided to no longer seek accelerated approval of odronextamab, a bispecific antibody (bsAb) CD20 x CD3, for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the company is continuing to pursue this approval for follicular lymphoma (FL), with an FDA[…]

Featured image of the article BioNTech, promising results in a clinical trial with a bispecific antibody therapy to treat breast cancer (BNT327).

BioNTech, promising results in a clinical trial with a bispecific antibody therapy to treat breast & lung cancers (BNT327)

Posted on by

SOPHIA ANTIPOLIS, France – February 4th, 2025 (last update 10th April, 2025) │ Advancements in oncology have consistently pushed the boundaries of therapeutic innovation, particularly in the realm of immunotherapy. BioNTech’s BNT327, a bispecific antibody targeting vascular endothelial growth factor (VEGF) and Programmed death-ligand 1 (PD-L1), represents a cutting-edge approach to treating difficult cancers such[…]